PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer

OBJECTIVES: This study aimed to investigate the anti‐PD‐1 inhibitor pembrolizumab as a potential agent for use in non‐muscle‐invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run‐in study to assess the safety and tolerability of intravesical pembrolizumab after transurethral resection o...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodcock, Victoria K., Chen, Ji‐Li, Purshouse, Karin, Butcher, Chrissie, Collins, Linda, Haddon, Caroline, Verrall, Gillian, Elhussein, Leena, Roberts, Corran, Tarlton, Andrea, Rei, Margarida, Napolitani, Giorgio, Salio, Mariolina, Middleton, Mark R., Cerundolo, Vincenzo, Crew, Jeremy, Protheroe, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071078/
https://www.ncbi.nlm.nih.gov/pubmed/37025470
http://dx.doi.org/10.1002/bco2.220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071078/
https://www.ncbi.nlm.nih.gov/pubmed/37025470
http://dx.doi.org/10.1002/bco2.220

Ejemplares similares